3SOF

Press Release Source: Generex Biotechnology Corporation


Generex Biotechnology Comments on Recent Trading Activity
Tuesday March 11, 8:00 am ET 
Rodman & Renshaw Analyst Reiterates Market Outperform Rating and $6 Price Target


WORCESTER, Mass.--(BUSINESS WIRE)--Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, commented on trading activity in its stock. The Company believes that the decline in its common stock yesterday was related to the decisions of Eli Lilly and Company as well as Pfizer and Novo Nordisk to discontinue the development of their inhaled insulin products. Generex believes that those decisions enhance its competitive position in the marketplace, as it removes potentially competitive products. Unlike safety concerns related to those products, Generex's proprietary platform technology delivers insulin into the human body through the oral cavity, with no deposit in the lungs. In clinical tests, the drug has always demonstrated an excellent safety profile. Generex recently commenced a Phase III study of its flagship product, Generex Oral-lyn™, which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007.


In a research report published yesterday by Navdeep S. Jaikaria, Ph.D., a Senior Biotechnology Analyst at Rodman & Renshaw, he reiterated his Market Outperform Rating on Generex and $6 price target. Some of the highlights of the report, titled, "NO IMPACT ON ORAL-LYN FROM LILLY TERMINATION OF ALKERMES INHALED INSULIN" were:

Alternative Insulin Competitors Continue to Fall and Enhance the Oral-ly Opportunity Last Friday, Alkermes Inc. (ALKS, Not Rated) announced that it received a letter from Eli Lilly (LLY, Not Rated) terminating their license agreement for the development of AIR Inhaled Insulin. This news, as well as the announcement in October 2007 by Pfizer Inc. (PFE, Not Rated) of the termination of its development of Exubera, an in-market inhalable insulin by Nektar Therapeutics Inc. (NKTR, Not Rated), have continued to place unwarranted pressure on the shares of Generex, which is in the final stages of preparation for a Phase III trial with Oral-lyn, the company's proprietary oral insulin product candidate. We believe disappointing sales with Exubera inhaled insulin made uncertain the prospects for further commercialization of Alkermes' AIR and AERx, an inhaled insulin system by Novo Nordisk A-S (NVO, Not Rated) whose Phase III development was discontinued in January 2008. We believe this news is positive for Generex as they enhance Oral-lyn's opportunity as a safe, more tolerable, non-injectable insulin for the treatment of patients with diabetes.

We Reiterate that the High Hurdles with the Inhaled Route of Insulin Delivery are Not Likely to be Observed with Buccal Cavity (Oral) Delivery of Insulin Concerns continue to grow that inhaled insulins, such as Exubera, may all be plagued by the observation of an early, non-progressive decline in lung function that does not improve over long-term use of Exubera, as well as problems associated with formulation of insulin into inhalable powder form. Further, the advancement of more convenient injectable devices, such as pens filled with pre-mixed insulin analogs, obviated the value of convenient mealtime titratable insulin delivery. We believe the significant hurdles seen with the inhalation route of delivery bode negative for inhaled insulin products, and open the door for Oral-lyn as the insulin potentially with the best non-injectable alternative route of mealtime insulin delivery.

About Generex

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. For more information, visit the Generex website at http://www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as ``expects,'' ``plans,'' ``intends,'' ``believes,'' ``will,'' ``estimates,'' ``forecasts,'' ``projects'' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any ``phase'' of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.



Contact:
CEOcast, Inc.
Gary Nash, 212-732-4300
or
American Capital Ventures, Inc.
For Generex:
Howard Gostfrand, 305-918-7000

--------------------------------------------------------------------------------
Source: Generex Biotechnology Corporation

UPDATE 2-Generex: stock drop related to inhaled insulin concerns
Tue Mar 11, 2008 11:01am EDT


March 11 (Reuters) - Generex Biotechnology Corp (GNBT,Trade) attributed the sharp decline of its stock price on Monday to a decision by several leading drugmakers to stop developing inhaled insulin products.

Shares of Generex, which is also developing an inhaled insulin product that is in a late-stage trial, fell as much as 20 percent on Monday. The company said unlike safety concerns related to other inhaled insulin products, its experimental Generex Oral-lyn delivers insulin into the body through the mouth, with no deposit in the lungs.

Eli Lilly & Co (LLY,Trade), which was developing an inhaled insulin treatment with Alkermes Inc (ALKS,Trade), was the latest drugmaker to terminate development of inhaled insulin and follows similar decisions by Pfizer Inc (PFE,Trade) and Novo Nordisk ((NOVOb.CO)).

In related news, Mannkind ((MNKD.O)) on Monday also said it was committed to developing its inhaled insulin product.

Shares of Generex rose about 13 percent before the bell to $1.06, after closing at 94 cents Monday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Bernard Orr)

Press Release Source: Generex Biotechnology Corp.


Generex Biotechnology Announces That Supplies for a Phase III Study of Generex Oral-lyn for a Number of Clinical Sites Have Been Packaged and are Ready for Shipping
Tuesday March 11, 12:00 pm ET
Initial Clinical Study Sites in the United States, Canada and Ukraine Primed to Dose Patients


WORCESTER, Mass., March 11, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that canisters of Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, have been labeled and packaged for Phase III clinical trial sites in the United States, Canada and Ukraine. Both placebo and active canisters are ready to be shipped to the clinical sites which will permit the initiation of the pivotal study. Clinical supplies of canisters for the balance of the sites are scheduled to be labeled and packaged in the next 45 days.


The Phase III protocol, identified as GEN084-OL, calls for a six-month trial which is expected to include 750 patients with Type-1 diabetes mellitus. The Company previously received a non-objection letter from Health Canada to conduct this pivotal study and the FDA did not object to the study. The primary objective of the study is to compare the efficacy of Generex Oral-lyn and the RapidMist Diabetes Management System with that of standard regular injectable human insulin therapy as measured by Hba1c in patients with Type-1 diabetes mellitus.

``We are systematically implementing our action plan to commence patient dosing at all global Phase III centers for our flagship product,'' said Anna Gluskin, the Company's President and Chief Executive Officer. ``We believe that our careful planning and attention to detail will ensure a smooth transition from drug handling to dosing. Previous studies conducted using Generex Oral-lyn have demonstrated an excellent safety profile and promising results, providing us with confidence that Generex Oral-lyn represents the first safe and effective alternative to needle sticks for millions of patients with diabetes.''

About Generex

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. The Company's flagship product, oral insulin (Generex Oral-lyn), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. For more information, visit the Generex website at http://www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as ``expects,'' ``plans,'' ``intends,'' ``believes,'' ``will,'' ``estimates,'' ``forecasts,'' ``projects'' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any ``phase'' of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.



Contact:
         For Generex Biotechnology Corporation:
         CEOcast, Inc.
         Gary Nash
         212-732-4300
         
         American Capital Ventures, Inc.
         Howard Gostfrand
         305-918-7000


--------------------------------------------------------------------------------
Source: Generex Biotechnology Corp.

Press Release Source: Generex Biotechnology Corp.


Generex Biotechnology Announces North American Initiation of Generex Oral-lyn Phase III Diabetes Study
Monday April 7, 9:30 am ET
Patient Screening Underway in North America for the Company's Non-Injectable Insulin That is Absorbed in the Lining of the Mouth and Does Not Enter the Lungs


WORCESTER, Mass., April 7, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has initiated the Phase III protocol in North America for its proprietary buccally-absorbed oral insulin spray product, Generex Oral-lyn(tm), with the commencement of patient screening. The first screening took place in late March in Texas. Other clinical sites participating in the study located in the United States are in Texas, Maryland, Minnesota and California, and in Canada in the province of Alberta.


The Phase III protocol, identified as GEN084-OL, calls for a six month trial which is expected to include 750 patients with Type-1 diabetes mellitus. The primary objective of the study is to compare the efficacy of Generex Oral-lyn and the RapidMist(tm) Diabetes Management System with that of standard regular injectable insulin therapy as measured by Hba1c in patients with Type-1 diabetes mellitus. Generex Oral-lyn is delivered into the mouth via the Company's proprietary RapidMist device. Unlike inhaled insulin products, buccally-absorbed Generex Oral-lyn does not enter the lungs.

``This clinical milestone represents a long history of research and development to optimization for Generex Oral-lyn which is now entering the final clinical stage in major jurisdictions,'' said George Markus, the Company's Vice President of Regulatory Affairs. ``Our product is designed to offer a safe and convenient alternative to prandial insulin injections which can improve treatment compliance and quality of life for patients with diabetes.''

Generex Oral-lyn is presently approved for commercial sale in India and Ecuador. The delivery of Generex Oral-lyn clinical supplies to global sites and centers, including Ukraine and Russia, is on-going with roll-out to other regions to follow.

About Generex

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. For more information, visit the Generex website at http://www.generex.com.

The Generex Biotechnology Corp. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as ``expects,'' ``plans,'' ``intends,'' ``believes,'' ``will,'' ``estimates,'' ``forecasts,'' ``projects'' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any ``phase'' of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.



Contact:
          CEOcast, Inc.
          Gary Nash
          212-732-4300

          American Capital Ventures, Inc.
          Howard Gostfrand
          305-918-7000


--------------------------------------------------------------------------------
Source: Generex Biotechnology Corp.



52wk Range: 0.81 - 2.14
Volume: 1,356,144
Avg Vol (3m): 838,587

Technicals
Close Above the 13-day MA
Percentage Gainer

Last Price Quote is:
5.59%above 13-day MA
-6.24%below 50-day MA
RS Rating: 10 

Fundamentals
Key Data:
Market Cap (M): $112.59 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 06/09/2008
Last Analyst Rating: Mkt Outperform

Hi,

Swing trade for SHORT...

Close at 0.60
Stop-loss at 0.69

Market Feeling the Flu...

The "Swine Flu" is all over the news but I can't find any related news @ GNBT or Antigen Express websites that they are working on a vaccine (which is what gave them the big jump with the "Avian Flu" scare). You'd think they'd be all over this.


52wk Range: 0.08 - 1.19
Volume: 43,459,563
Avg Vol (3m): 2,377,650

Technicals
Close Above the 50-day MA
Close Above the 13-day MA
Most Actives
Percentage Gainer

Last Price Quote is:
109.23%above 13-day MA
109.21%above 50-day MA
RS Rating: 55 

Fundamentals
Key Data:
Market Cap (M): $45.40 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform

active in the pre market...

•Swine Flu Index Back on the Radar
Indie Research(Wed 12:09pm)

Swine Flu Index Takes Top Spot 6/4/09 

Multiple vaccine companies made news on Thursday, sending the sector higher.

Today it was announced that the National Institutes of Health will test Novavax's (NVAX) VLP technology, which according to the company is able to produce H1/N1 targeted vaccines within weeks. Novavax said that it has already produced enough of the vaccine for animal testing, which the Centers for Disease Control plan to commence. Shares are skyrocketing today by over 50% on the news.

As a whole, the Swine Flu and Bird Flu Stocks Index is up by 7.2%. It is now beating the S&P 500 by 59.2% over the last month.

Generex Biotechnology (GNBT) also made news today, announcing that it will present at the American Diabetes Association's annual meeting, held Friday through Tuesday. The company specializes in drug delivery through mouth lining in treatment of metabolic diseases. Shares are up by 30% on the day.

Hemispherx Biopharma (HEB) is up by 14% today after Japanese researchers named its drug technology the "most promising mucosal adjuvant for influenza."

Alpha Pro Tech (APT) also made an announcement today, stating that it will report record second-quarter sales. The company cited its ability to increase manufacturing to meet accelerated demand for its respirator masks amid the swine flu scare. Shares are up by 9%.

The multi-billion dollar players are mixed today. Sanofi-Aventis (SNY) is up by 4% while GlaxoSmithKline (GSK) is up fractionally. Gilead Sciences (GILD) is up by less than 1%.

Dynavax Technologies (DVAX) is giving back some of yesterday's gains. The stock is an industry laggard today, falling by more than -12%.

As of this writing the Swine Flu and Bird Flu Stocks Index is the top performing tickerspy Index over the last month, gaining 52.8%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Tags: APT, DVAX, GILD, GNBT, GSK, HEB, NVAX, SNY

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3

A 'Pandemic' Now Declared, Focus Back on Swine Flu Stocks
On Friday June 12, 2009, 12:00 pm EDT

The H1N1 virus is officially a pandemic, and vaccine stocks are responding.

Swine flu stocks are up again today, with some extending weekly gains to more than 20%. A number of companies released good news to end the week. From small-cap players to multi-billion dollar giants, shares are up big on high volume. Novartis (NYSE: NVS) announced today that it will have a swine flu vaccine ready by this fall. Shares are up by 4% on the news.

On Thursday, the World Health Organization raised its alert level on the virus to "Phase 6," indicating that it has officially become a pandemic.

As a whole the Swine Flu and Bird Flu Stocks Index is up by 2.5%. It is now beating the S&P 500 by 35.5% over the last month.

Generex Biotechnology (NASDAQ: GNBT) is leading the Index today with 10% gains. The company was granted five new patents for its drug delivery systems. The patents were awarded in Canada, Australia, New Zealand, Brazil, and Lebanon. The stock is still in negative territory this week by -3%.

Sinovac Biotech (AMEX: SVA) is adding another 3% to its industry-leading 30% weekly rally. On Monday the company announced that it had begun production of a swine flu vaccine, and noted that it could produce up to 30 million doses per year.

Vical (NASDAQ: VICL) has fallen from earlier highs, and is now trading up fractionally. Thomas Weisel initiated coverage of the company today with an Overweight rating and a $5 price target. The analyst cited Vical's proprietary technology, strategic partnerships, and licensing agreements.

GlaxoSmithKline (NYSE: GSK) and Hemispherx Biopharma (AMEX: HEB) are both ahead by more than 4% today.

Pure Bioscience (NASDAQ: PURE) and AVI Biopharma (NASDAQ: AVII) are industry laggards today, falling by -3% and -6% respectively.

As of this writing the Swine Flu and Bird Flu Stocks Index is a top-three performing tickerspy Index over the last month, gaining 39.5%.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.

Investors can follow the Swine Flu and Bird Flu Stocks Index and view related performance charts and metrics at tickerspy.com.
http://www.tickerspy.com/index/Swine-Flu-and-Bird-Flu-Stocks?refer=2028Y3
   

updated chart look...

Beacon Equity Issues Trading Outlook for Generex Biotechnology Corp.
Press Release
Source: Beacon Equity
On Monday July 27, 2009, 6:50 am EDT

DALLAS, July 27, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Generex Biotechnology Corp. (Nasdaq:GNBT - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Generex Biotechnology Corp. (Nasdaq:GNBT - News) should be of particular interest to other pharmaceutical companies: CPEX Pharmaceuticals Inc. (Nasdaq:CPEX - News), Mannkind Corp. (Nasdaq:MNKD - News), Novo Nordisk A/S (NYSE:NVO - News), Life Technologies Corp. (Nasdaq:LIFE - News), King Pharmaceuticals (NYSE:KG - News) and Mylan Inc. (Nasdaq:MYL - News).

It is available at: http://www.beaconequity.com/i/GNBT

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Generex Biotechnology Corp. (GNBT) is a development-stage biopharmaceutical company engaged in research, development and commercialization of its proprietary platform technology for oral administration to treat metabolic and immunological diseases. The Company specializes in oral (buccal) cavity administration, using a hand-held aerosol applicator, of proteins, peptides, monoclonal antibodies, hormones and vaccines.

In the report, the analyst notes:

"The Company operates in an approximately $21 billion oral anti-diabetic market, which is growing at roughly 6% per year. Research company Visiongain predicts continued significant market growth as the population in the OECD countries median age climbs.

"On July 20, the Company announced the release of a study which demonstrates the results of a novel Ii-Key/HPV immunotherapeutic vaccine, details of which appear in the July 2009 edition of trade magazine, Vaccine. The study demonstrates an additional application of the Ii-Key technology platform, which is presently developed by the Company's solely owned subsidiary Antigen Express. Another peptide, AE37, of this application is currently in phase II trials for the treatment of breast cancer and phase I trials for the treatment of prostate cancer."

To read the entire report visit: http://www.beaconequity.com/i/GNBT

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.beaconequity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Contact:
Beacon Equity ResearchJeff Bishop(469)[email protected]

Updated chart scene...
Nice chart, still looking for that solid close above 0.72
Forming strong base structures so not too worried.

52wk Range: 0.08 - 1.14
Volume: 11,692,538
Avg Vol (3m): 10,298,900

Technicals
Most Actives

Last Price Quote is:
16.08%above 13-day MA
28.69%above 50-day MA
RS Rating: 97  

Fundamentals
Key Data:
Market Cap (M): $123.74  
P/E Ratio: NA  
PEG Ratio: N/A  
Next Earnings: N/A
Last Analyst Rating: Mkt Outperform

100,000 last week in UK H1N1

"Flu in England Hits Decade High as Pandemic Spreads"

(Bloomberg) -- England and Wales are suffering the worst bout of flu in a decade, kindled by international travel and later school breaks than in the rest of Europe.

Doctors reported 155 cases of flu-like illness per 100,000 people across the two countries in the week ended July 19, the Royal College of General Practitioners said today. The number of swine flu cases in the U.K. rose by 100,000 in the past week, Britain's Chief Medical Officer Liam Donaldson said.

"It's highly unusual to get any rise of that sort during the summer months," Donaldson said at a briefing in London today.

There have been 840 hospitalizations linked to the pandemic flu and the death toll was unchanged from a week ago at 26, he said. London's Tower Hamlets is still the regional health authority with the highest rate of medical consultations for flu-like illness in England and six of the country's top 10 areas are in the capital, he said. Even northern regions such as Yorkshire and Humber are "up to the highest levels of flu activities," he said.

The rate of infection in England and Wales is the highest since the winter of 2000 and double that of the previous week, the Royal College's research and surveillance center in Birmingham said. Rates may continue to climb as the first influenza pandemic in 41 years spreads among people with no immunity to the new H1N1 strain, said John Paget, an epidemiologist at the Utrecht-based Netherlands Institute for Health Services Research.

'Totally Unusual'

"The curve is going straight up," said Paget, who monitors flu patterns for euroflu.org. "This is totally unusual. It just confirms that it's a pandemic virus."

The influx of travelers arriving at London's airports probably meant the country was "sufficiently seeded with the virus when the schools were still open." This wasn't the case on the continent, Paget said. He expects flu rates to surge there once children return to school.

London's Heathrow airport is Europe's busiest, with 66.9 million passengers using it in 2008, according to the U.K. Civil Aviation Authority.

Children tend to speed transmission of the disease because they spend the school day in groups and they're more susceptible to flu than adults. So far, 60 percent of the world's reported swine flu cases occurred in those aged 18 or younger, researchers said in a study published in The Lancet this week.

School Closings

"The schools in England have only just closed, and we know that has a big effect," said Hugh Pennington, a retired microbiologist and emeritus professor of bacteriology at the University of Aberdeen, Scotland. In France, by contrast, school ended the week of June 29.

Governments worldwide are battling the H1N1 virus, which has taken root across the globe faster than any previous flu pandemic, according to the Geneva-based World Health Organization. Donaldson last week said the National Health Service is bracing for as many as 65,000 deaths from the disease."

GNBT  -  Volume Alert
http://www.chartmoney.com/stockquotes.php?ticker=gnbt
Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.